Stifel lowered the firm’s price target on Affimed (AFMD) to $4 from $5 and keeps a Hold rating on the shares after the company provided granularity on the timing and setting of data disclosures into year-end along with its Q3 results. The firm has updated its model for the quarter to reflect the updated cash balance of $26M, the analyst noted.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AFMD: